vs
Side-by-side financial comparison of Beam Global (BEEM) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $9.0M, roughly 1.5× Beam Global). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -25.8%, a 101.5% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-3.8M).
Suntory Global Spirits Inc., formerly known as Beam Suntory, Inc., and before that as Beam, Inc., is an American beverage company that is a subsidiary of Suntory Holdings, a Japanese multinational beverage conglomerate. The company produces alcoholic beverages.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
BEEM vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.0M | $13.7M |
| Net Profit | $-2.3M | $10.4M |
| Gross Margin | 17.8% | — |
| Operating Margin | -29.3% | -86.5% |
| Net Margin | -25.8% | 75.7% |
| Revenue YoY | 6.7% | — |
| Net Profit YoY | 49.6% | 179.1% |
| EPS (diluted) | — | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.0M | $13.7M | ||
| Q3 25 | $5.8M | $19.1M | ||
| Q2 25 | $7.1M | $8.1M | ||
| Q1 25 | $6.3M | $2.9M | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $11.5M | — | ||
| Q2 24 | $14.8M | — | ||
| Q1 24 | $14.6M | — |
| Q4 25 | $-2.3M | $10.4M | ||
| Q3 25 | $-4.9M | $-16.3M | ||
| Q2 25 | $-4.3M | $-15.8M | ||
| Q1 25 | $-15.5M | $-13.3M | ||
| Q4 24 | $-4.6M | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $-4.9M | — | ||
| Q1 24 | $-3.0M | — |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -0.5% | — | ||
| Q2 25 | 20.3% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | 15.9% | — | ||
| Q1 24 | 10.2% | — |
| Q4 25 | -29.3% | -86.5% | ||
| Q3 25 | -84.2% | -10.1% | ||
| Q2 25 | -63.1% | -177.7% | ||
| Q1 25 | -245.8% | -472.7% | ||
| Q4 24 | -60.1% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | -32.3% | — | ||
| Q1 24 | -20.9% | — |
| Q4 25 | -25.8% | 75.7% | ||
| Q3 25 | -84.1% | -85.4% | ||
| Q2 25 | -60.5% | -196.0% | ||
| Q1 25 | -245.5% | -452.7% | ||
| Q4 24 | -54.5% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | -33.2% | — | ||
| Q1 24 | -20.9% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | $-0.28 | $-0.11 | ||
| Q2 25 | $-0.28 | $-0.16 | ||
| Q1 25 | $-1.04 | $-0.18 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $969.0K | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $24.8M | $35.3M |
| Total Assets | $42.7M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $969.0K | $137.5M | ||
| Q3 25 | $3.3M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $24.8M | $35.3M | ||
| Q3 25 | $26.5M | $-8.1M | ||
| Q2 25 | $26.9M | $7.1M | ||
| Q1 25 | $26.7M | $10.7M | ||
| Q4 24 | $41.3M | — | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.4M | — | ||
| Q1 24 | $46.9M | — |
| Q4 25 | $42.7M | $154.7M | ||
| Q3 25 | $44.6M | $133.7M | ||
| Q2 25 | $46.7M | $133.8M | ||
| Q1 25 | $46.8M | $103.7M | ||
| Q4 24 | $61.5M | — | ||
| Q3 24 | $67.3M | — | ||
| Q2 24 | $71.9M | — | ||
| Q1 24 | $75.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.8M | $-2.0M |
| Free Cash FlowOCF − Capex | $-3.8M | $-2.1M |
| FCF MarginFCF / Revenue | -42.3% | -15.3% |
| Capex IntensityCapex / Revenue | 0.6% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.8M | $-2.0M | ||
| Q3 25 | $-4.6M | $-17.5M | ||
| Q2 25 | $-318.0K | $-14.5M | ||
| Q1 25 | $-1.8M | $29.0M | ||
| Q4 24 | $859.0K | — | ||
| Q3 24 | $-3.0M | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $-3.0M | — |
| Q4 25 | $-3.8M | $-2.1M | ||
| Q3 25 | $-5.1M | — | ||
| Q2 25 | $-1.1M | $-14.9M | ||
| Q1 25 | $-1.8M | $29.0M | ||
| Q4 24 | $462.0K | — | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-3.1M | — |
| Q4 25 | -42.3% | -15.3% | ||
| Q3 25 | -87.9% | — | ||
| Q2 25 | -15.2% | -184.0% | ||
| Q1 25 | -28.7% | 988.3% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | -27.4% | — | ||
| Q2 24 | 18.9% | — | ||
| Q1 24 | -21.5% | — |
| Q4 25 | 0.6% | 0.7% | ||
| Q3 25 | 7.8% | 0.0% | ||
| Q2 25 | 10.7% | 5.0% | ||
| Q1 25 | 0.9% | 0.8% | ||
| Q4 24 | 4.7% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.28× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BEEM
| Products | $7.0M | 77% |
| Other | $2.0M | 23% |
XLO
Segment breakdown not available.
